A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

NCT07215312 · tracked via the Priya Life Science USA tracker

Sponsor

Eli Lilly and Company

Phase

Phase 2

Started

2025-10-13

Last updated

2026-07-13

Condition(s) studied

Diabetes Mellitus, Type 2

Investigational drug(s) / intervention(s)

LY3938577Degludec

LY3938577: Administered SC

Degludec: Administered SC

Study summary

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: * Have type 2 diabetes * Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening * Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive * Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2) Exclusion Criteria: * Have type 1 diabetes

Primary outcome measure(s)

Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) — Baseline through Week 20

Trial sites (26)

Facility	City	Region
Tucson Clinical Research Institute	Tucson	Arizona
Encompass Clinical Research	Spring Valley	California
University Clinical Investigators, Inc.	Tustin	California
Tampa Bay Medical Research	Clearwater	Florida
Encore Medical Research	Hollywood	Florida
Clinical Research of Central Florida	Lakeland	Florida
Encore Medical Research - Weston	Weston	Florida
Iowa Diabetes and Endocrinology Research Center	West Des Moines	Iowa
Washington University School of Medicine	St Louis	Missouri
Accellacare - Wilmington	Wilmington	North Carolina
AMR Clinical	Norman	Oklahoma
Tribe Clinical Research, LLC	Greenville	South Carolina
Holston Medical Group	Bristol	Tennessee
Texas Diabetes & Endocrinology, P.A.	Austin	Texas
Velocity Clinical Research, Dallas	Dallas	Texas
Juno Research	Houston	Texas
Southern Endocrinology Associates	Mesquite	Texas
Consano Clinical Research, LLC	Shavano Park	Texas
Texas Valley Clinical Research	Weslaco	Texas
Chrysalis Clinical Research	St. George	Utah
Cicemo Srl	Buenos Aires	Argentina
CIPREC	Buenos Aires	Argentina
Mautalen Salud e Investigación	Buenos Aires	Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada	Buenos Aires	Argentina
Instituto Centenario	CABA	Argentina
Instituto Médico Catamarca IMEC	Rosario	Argentina

More Eli Lilly and Company trials in the USA

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease Recruiting

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine Active, not recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Recruiting

Other trials for the same condition

ROME GS System Study Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes Recruiting

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Recruiting

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes Recruiting

Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07215312 on ClinicalTrials.gov ↗ ← All trials in the USA